Compare
Lineage Cell Therapeutics, Inc. vs Relay Therapeutics, Inc. vs Pelthos Therapeutics Inc. vs Caribou Biosciences, Inc.
| Latest fiscal year | Lineage Cell Therapeutics, Inc. LCTX | Relay Therapeutics, Inc. RLAY | Pelthos Therapeutics Inc. PTHS | Caribou Biosciences, Inc. CRBU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.56M | $15.36M | $16.80M | $11.16M |
| Revenue growth (YoY) | +53.2% | +53.4% | n/a | +11.7% |
| Gross margin | n/a | n/a | 76.3% (computed) | n/a |
| Operating margin | -251.6% | n/m | -193.1% | n/m |
| Net margin | -436.5% | n/m | -257.9% | n/m |
| Net income | -$63.53M | -$276.48M | -$43.32M | -$148.12M |
| EPS (Diluted) | -$0.28 | -$1.61 | -$23.04 | -$1.59 |
| Operating cash flow | -$18.92M | -$235.46M | -$22.59M | -$110.99M |
| Free cash flow | -$19.44M | -$235.87M | -$22.69M | -$112.35M |
| Cash & equivalents | $40.79M | $84.02M | $17.97M | $12.36M |
| Total assets | $112.58M | $621.33M | $130.40M | $175.37M |
| Total liabilities | $69.24M | $54.27M | $91.52M | $53.19M |
| Shareholders' equity | $43.35M | $567.06M | $38.88M | $122.17M |
| Return on year-end equity | -146.6% | -48.8% | -111.4% | -121.2% |
| Shares outstanding | 243.12M | 173.87M | 3.23M | 95.14M |
Revenue, most recent five fiscal years
| Fiscal year | Lineage Cell Therapeutics, Inc. | Relay Therapeutics, Inc. | Pelthos Therapeutics Inc. | Caribou Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $14.56M Ended 2025-12-31 | $15.36M Ended 2025-12-31 | $16.80M Ended 2025-12-31 | $11.16M Ended 2025-12-31 |
| 1 year earlier | $9.50M Ended 2024-12-31 | $10.01M Ended 2024-12-31 | $0 Ended 2024-12-31 | $9.99M Ended 2024-12-31 |
| 2 years earlier | $8.95M Ended 2023-12-31 | $25.55M Ended 2023-12-31 | n/a | $34.48M Ended 2023-12-31 |
| 3 years earlier | $14.70M Ended 2022-12-31 | $1.38M Ended 2022-12-31 | n/a | $13.85M Ended 2022-12-31 |
| 4 years earlier | $4.34M Ended 2021-12-31 | $3.03M Ended 2021-12-31 | n/a | $9.60M Ended 2021-12-31 |